( May 22, 2026, 1:12 PM EDT) -- WASHINGON, D.C. — The U.S. Supreme Court should deny a petition for a writ of certiorari on whether state unfair competition laws are preempted by federal law in cases accusing compounding pharmacies of marketing drugs without premarket approval by the U.S. Food and Drug Administration because the lower court got it right and the FDA “is currently considering whether to take regulatory action with respect to the drug at issue here,” the federal government contends in a May 21 amicus curiae brief....